The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502).
 
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
 
Farshad Foroudi
No Relationships to Disclose
 
Nathan Lawrentschuk
No Relationships to Disclose
 
Laura Galleta
No Relationships to Disclose
 
Amanda Seegum
No Relationships to Disclose
 
Alan Herschtal
No Relationships to Disclose
 
Emma Link
Patents, Royalties, Other Intellectual Property - Emma is an innovator: the discovery of her DPhil has been the subject of patent applications in the USA, UK, Europe, China, and Japan. The US rights to the patent were granted to Boston Heart Diagnostics which optimised the test on their technology platfo
 
Margaret Mary McJannett
Honoraria - Mundipharma
 
Elizabeth Chien Hern Liow
Travel, Accommodations, Expenses - Pfizer
 
Peter S. Grimison
Research Funding - ASLAN Pharmaceuticals (Inst); Boston Biomedical (Inst); Eisai (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); Specialised Therapeutics; Tigermed (Inst); Tilray (Inst); Zucero Therapeutics
 
Alison Yan Zhang
Honoraria - Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Mundipharma; Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
NItya Patanjali
No Relationships to Disclose
 
Siobhan Ng
Honoraria - Amgen; Astellas Pharma; Bayer; Ipsen; Johnson & Johnson; Johnson & Johnson; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Robert Goodwin
Travel, Accommodations, Expenses - Mundipharma
 
Colin Tang
No Relationships to Disclose
 
Colin Chen
No Relationships to Disclose
 
Elizabeth J. Hovey
Consulting or Advisory Role - Amgen; Janssen
Travel, Accommodations, Expenses - Amgen
 
George Hruby
No Relationships to Disclose
 
Alexander David Guminski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Pfizer; Prime Oncology; Regeneron; Sun Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medivation/Astellas; Merck KGaA; Sun Pharma
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.